DEFA14A ·Filed Jun 29, 2026

ANAB

ANAPTYSBIO, INC
NEUTRAL
Impact 2/10
Horizonweeks Processed3mo ago SEC0001193125-26-288431
Proxy solicitation materials
Actionable Insight • Neutral

This is a routine proxy reminder — no material new information. The equity plan amendment could be dilutive if it adds significant share reserves, but details are not in this filing. Monitor the definitive proxy statement for share counts. The meeting is six weeks away; no immediate trading catalyst.

DirectionNeutral
Confidencehigh
Horizonweeks
Final — all horizons settled through T+60d ⚠ clustered
ANAB ▼ -24.79% at T+60d
NEUTRAL call ✗ call lost -24.79% · α vs SPY -28.35% · entry $67.50 → $50.77
Entry anchored
Jun 29, 03:59 PM ET
via exchange tick
T+1d
-3.07%
call -3.07% · α -2.93%
$65.43
settled 3mo ago
T+5d
-7.69%
call -7.69% · α -8.29%
$62.31
settled 3mo ago
T+20d
-20.58%
call -20.58% · α -19.55%
$53.61
settled 2mo ago
T+60d
-24.79%
call -24.79% · α -28.35%
$50.77
settled 9d ago

Price Chart

Loading chart...

Executive Summary

AnaptysBio filed definitive additional proxy soliciting materials (DEFA14A) for its August 11, 2026 Annual Meeting. The board recommends voting FOR all four proposals: electing two Class III directors (Hollings Renton and John P. Schmid), ratifying KPMG LLP as auditor, approving say-on-pay, and amending the 2017 Equity Incentive Plan. This is a routine management proxy solicitation with no contested matters or activist involvement.

Key Facts

  • Annual Meeting scheduled for August 11, 2026 at 9:00 AM Pacific Time
  • Record date for stockholders is June 22, 2026
  • Board recommends FOR votes on all four proposals
  • Proposals include election of two Class III directors, auditor ratification, say-on-pay vote, and equity plan amendment
  • Director nominees: Hollings Renton and John P. Schmid
  • KPMG LLP proposed as independent auditor for fiscal year ending June 30, 2027
  • This is definitive additional materials (DEFA14A), not the definitive proxy statement itself

Financial Impact

No financial figures disclosed in this filing. The equity plan amendment may involve share reserve increases but no amounts are stated.

equity_compensationshareholder_voting

Risk Factors

  • Equity plan amendment could be dilutive if share reserve increase is large
  • Say-on-pay vote may receive low support if compensation practices are controversial, though no opposition has been filed

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
94% bullish (17 analysts)

Investment Themes

Biotech & Drug Discovery

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
DEFA14A Filing (Primary)0001193125-26-288431
Document: 0001193125-26-288431-index-headers.html0001193125-26-288431
Document: 0001193125-26-288431-index.html0001193125-26-288431
Document: 0001193125-26-288431.txt0001193125-26-288431
24 reports for ANAB
Performance horizon
67% Hit rate 12 of 18 directional calls best @ T+60▲ +41.26%Mar 3, 2026
Filters
Rows
Reports for ANAB — sortable, filterable
TypeNow
Aug 12, 2026
7w ago
Institutional Cluster
BULLISH ★ 5/10
$56.02 $53.87▼ −3.84%▼ −2.09%$48.53 (−13.37%)
Jun 29, 2026
13w ago
144
BEARISH ★ 6/10
$67.50 $53.61▲ +20.58%▲ +19.55%$48.53 (+28.10%)
Jun 29, 2026
13w ago
DEFA14A
NEUTRAL ★ 2/10
$67.50 $53.61▼ −20.58%▼ −19.55%$48.53 (−28.10%)
Jun 26, 2026
14w ago
144
BEARISH ★ 6/10
$65.97 $54.15▲ +17.92%▲ +17.64%$48.53 (+26.44%)
Jun 22, 2026
14w ago
8-K
NEUTRAL ★ 2/10
$59.43 $50.29▼ −15.38%▼ −16.54%$48.53 (−18.34%)
Jun 17, 2026
15w ago
144
BEARISH ★ 5/10
$57.51 $54.15▲ +5.84%▲ +6.38%$48.53 (+15.61%)
Jun 15, 2026
15w ago
144
BEARISH ★ 6/10
$57.61 $62.51▼ −8.51%▼ −8.31%$48.53 (+15.76%)
Jun 11, 2026
16w ago
144
BEARISH ★ 6/10
$56.07 $66.39▼ −18.41%▼ −16.63%$48.53 (+13.45%)
Jun 10, 2026
16w ago
144
BEARISH ★ 5/10
$54.24 $66.59▼ −22.77%▼ −20.88%$48.53 (+10.53%)
Jun 8, 2026
16w ago
144
BEARISH ★ 5/10
$51.63 $67.33▼ −30.40%▼ −28.95%$48.53 (+6.00%)
Showing 10 of 24

US Market Status

Market Closed — Opens Mon (64h 22m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access